Key result
Inpatient antiplatelets treat ~81% of non-cardioembolic strokes, with DAPT favored in milder cases.
Why the study?
Real-world data on treatment patterns and adherence across severity levels are limited for non-cardioembolic ischaemic stroke.
What are the inpatient and discharge antiplatelet treatment patterns by stroke severity in patients with non-cardioembolic ischaemic stroke?
Population
180,021 adults hospitalised with a first NCIS in a US database
Comparison
Inpatient and discharge treatment patterns compared across NCIS severity levels
Design
Retrospective cohort study
Authors
Loading...
Broad APT adoption in stroke care supports current guidelines; leaves open research into treatment gaps and individualized approaches.
Cohort (n=180,021)
Yes
What are the inpatient and discharge antiplatelet treatment patterns by stroke severity in patients with non-cardioembolic ischaemic stroke?
In a large US cohort of patients with non-cardioembolic ischemic stroke, antiplatelet therapy was widely used, with dual antiplatelet therapy more frequently prescribed for milder strokes.
Savitz et al. (2026) conducted a cohort in Non-cardioembolic ischaemic stroke (NCIS) (n=180,021). Antiplatelet therapy (SAPT and DAPT) vs. Across stroke severity levels (NIHSS) was evaluated on Inpatient antiplatelet therapy (APT) use. In a US cohort of 180,021 patients with non-cardioembolic ischaemic stroke, 80.5% received inpatient antiplatelet therapy, with dual antiplatelet therapy used more frequently in milder strokes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: